Kubient (NasdaqCM: KBNT, KBNTW) (“Kubient” or the “Company”), a cloud-based software platform for digital advertising, announced today that the United States Patent and Trademark Office (“USPTO”) had issued its patent for the Company’s proprietary ad fraud identification and prevention technology, Kubient Artificial intelligence (“KAI”). The patent provides Kubient with intellectual property protection for KAI from now until 2040.
Lineage Cell Therapeutics Q4 EPS $(0.03) Beats $(0.04) Estimate, Sales $1.90M Miss $2.57M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 82.35 percent increase over losses of $(0.17) per share
